Semaglutide vs Wegovy: Same Molecule, Different Context?
Quick Answer
Semaglutide is the active pharmaceutical compound, a GLP-1 receptor agonist studied for metabolic and appetite-related outcomes. Wegovy is Novo Nordisk's brand name for semaglutide at 2.4 mg weekly, with FDA approval for chronic weight management. They share the same molecule but differ in dose, regulatory status, and how they are accessed and used.
What Is Semaglutide?
Semaglutide is a long-acting synthetic GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a naturally occurring gut hormone released after eating. The compound works by slowing gastric emptying and signaling the brain's satiety centers, which reduces appetite-driven behavior.
Its half-life is approximately one week, making it well-suited for once-weekly injection protocols . The molecule was first developed for blood glucose management in people with type 2 diabetes, under the brand name Ozempic, at doses of 0.5 mg, 1.0 mg, and 2.0 mg weekly . An oral formulation called Rybelsus uses doses of 3 mg, 7 mg, and 14 mg daily .
In research settings, semaglutide is studied across a wide dose range:
- Starting dose: 0.25 mg weekly for the first four weeks
- Maintenance range: 0.5 mg to 2.4 mg weekly depending on response and tolerance
Evidence level: High. The STEP trial program includes multiple large randomized controlled studies .
What Is Wegovy?
Wegovy is the brand name for semaglutide at its highest studied injectable dose, 2.4 mg weekly. Novo Nordisk received FDA approval for Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition .
The formulation is delivered by subcutaneous injection once weekly. Patients titrate upward over 16 to 20 weeks to reach the 2.4 mg maintenance dose, a protocol designed to reduce gastrointestinal side effects during adjustment .
In the STEP 1 clinical trial, participants using Wegovy at 2.4 mg weekly achieved an average body weight reduction of approximately 14.9% over 68 weeks compared to placebo . Cardiovascular outcomes were also studied in the SELECT trial, published in 2023 .
Evidence level: Very high. Phase 3 clinical trials with FDA approval.
Semaglutide vs Wegovy: Side-by-Side Comparison
| Feature | Semaglutide (research/compounded) | Wegovy (branded) |
|---|---|---|
| Type/form | Synthetic GLP-1 agonist peptide | Branded semaglutide, same molecule |
| Mechanism | GLP-1 receptor activation, appetite and gastric signaling | Identical mechanism |
| Typical research dose | 0.25 mg to 2.4 mg weekly, titrated | 2.4 mg weekly after titration |
| Evidence level | High, multiple RCTs | Very high, FDA-approved phase 3 trials |
Key Differences
The most important distinction is regulatory status. Wegovy is an FDA-approved drug product with defined manufacturing standards, verified purity, and specific labeling for its indication. Semaglutide in research or compounded form exists outside that framework, which creates questions about consistency, dosing accuracy, and quality control.
Second is the dose ceiling. Wegovy is specifically designed around the 2.4 mg weekly maintenance dose. Other semaglutide formulations, like Ozempic, reach a maximum of 2.0 mg weekly for their approved indication. Accessing the 2.4 mg level through compounded or research channels means operating without the standardized titration guidance built into Wegovy's prescribing protocol.
Third is access and cost. Wegovy requires a prescription and has faced supply shortages since its approval in 2021 . During shortage periods, compounded semaglutide products entered the market to fill demand, though these are not FDA-approved and are not considered equivalent in regulatory terms. The list price of Wegovy without insurance has exceeded $1,300 per month . Compounded versions have generally been cheaper, though quality and concentration accuracy can vary significantly between compounding pharmacies.
For people actively tracking their GLP-1 protocols and researching how different peptide compounds fit into their personal health data, DoseVault provides a structured way to log doses, monitor patterns, and organize research notes over time.
Fourth is the available safety data. Wegovy's phase 3 trials involved thousands of participants over extended periods . Compounded semaglutide has no comparable trial data, meaning users have less visibility into long-term safety profiles under compounded-specific manufacturing conditions.
Can You Stack Them?
Stacking does not apply here in the typical peptide sense, since Wegovy is semaglutide. Using both would mean doubling up on the same molecule, which carries real risk of overdose-level GI effects, potential cardiovascular stress, and hypoglycemia in certain individuals.
What some researchers explore is combining semaglutide with compounds that support muscle preservation. GLP-1 agonists can contribute to lean mass loss alongside fat loss during caloric deficit phases . Some protocols layer in peptides like BPC-157 or use resistance training programs alongside semaglutide use, though no formal clinical data exists on these stacks.
Any protocol combining GLP-1 class compounds with other metabolic or hormonal agents should be reviewed by a licensed clinician. The interaction risks are not fully characterized in the research literature.
Frequently Asked Questions
Is semaglutide the same thing as Wegovy?
Yes and no. Semaglutide is the active molecule. Wegovy is the brand name for semaglutide at a specific FDA-approved dose of 2.4 mg weekly for weight management.
What dose does Wegovy use compared to other semaglutide forms?
Wegovy uses 2.4 mg weekly. Ozempic, the diabetes formulation of semaglutide, uses up to 2.0 mg weekly. Research titration protocols typically start at 0.25 mg weekly .
Can compounded semaglutide be used instead of Wegovy?
Compounded semaglutide has been used when brand-name supply was limited, but compounded versions are not FDA-approved and may differ in purity and concentration. Always consult a licensed clinician before use.
What are the main side effects people report with semaglutide-based compounds?
Commonly reported side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose titration. These effects tend to decrease as the body adjusts over several weeks .
Who Picks Each, and When?
Research-oriented users exploring semaglutide broadly:
- Interested in GLP-1 mechanisms across a range of dose levels
- Accessing compounded or peptide-grade sources due to cost or prescription availability
- Tracking dose-response data and wanting flexibility in titration pace
Users seeking or already using Wegovy specifically:
- Have a prescription and are working within a supervised clinical program
- Want the regulatory assurance that comes with an FDA-approved product
- Are following the defined Wegovy titration schedule with a healthcare provider
Neither path is without tradeoffs. Wegovy provides the highest regulatory confidence and the most clinical trial backing. Research semaglutide offers flexibility and lower cost but significantly less oversight and consistency.
Related
- Semaglutide
- AOD-9604 vs Semaglutide
- Are Research Peptides the Same as Prescription Peptides?
- Berberine vs Semaglutide
- How to Reconstitute Semaglutide
- Peptides for Fat Loss
Disclaimer: This content is for educational purposes only. It is not medical advice. Semaglutide-based compounds, including Wegovy, require clinical supervision and are not appropriate for unsupervised use. These compounds are not FDA-approved for general research or self-administration outside of a licensed prescribing context. Always consult a licensed healthcare provider before beginning, adjusting, or stopping any peptide or pharmaceutical protocol.
Built by medical professionals, gym rats, and experienced biohackers
Ready to organize your GLP-1 research and track how your protocol evolves over time? DoseVault is built for people who take their health data seriously, with tools to log doses, track progress, and stay on top of what the research actually says.